Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review)

Molecular Medicine Reports

Volumn 1, Issue 2, 2008, Pages 139-160

  Steelman, Linda S ^a   Navolanic, Patrick M ^a   Franklin, Richard A ^a   Bonati, Antonio ^b   Libra, Massimo ^c   Stivala, Franca ^c   Martelli, Alberto M ^d,e   McCubrey, James A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e CNR   (Italy)

Author keywords

Breast cancer; Conventional therapy; Signal transduction inhibitors; Targeted therapy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 7 HYDROXYSTAUROSPORINE; A 443654; ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; B RAF KINASE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; EXEMESTANE; FLUDARABINE; FLUOROURACIL; GELDANAMYCIN; IMATINIB; L 779450; LETROZOLE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; NAVELBINE; PACLITAXEL; PX 866; RAF PROTEIN; RAPAMYCIN; SORAFENIB; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER THERAPY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; MUTATION; NEOPLASM; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 69249093407     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: None     Document Type: Review

References (335)

1. Centers for Disease Control and Prevention: Cancer: symptoms of breast cancer. Atlanta, GA, Centers for Disease Control and Prevention, http://www.cdc.gov/cancer/breast/basic-info/symptoms.htm, 2006.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 54: 8-29, 2004.
3. Meyn RE, Stephens LC, Hunter NR and Milas L: Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol 33: 410-414, 1994. (Pubitemid 24057693)
4. Schwartz PS and Waxman DJ: Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 60: 1268-1279, 2001. (Pubitemid 33144898)
5. Goodman MF, Bessman MJ and Bachur NR: Adriamycin and daunorubicin inhibition of mutant T4 DNA polymerase. Proc Natl Acad Sci USA 71: 1193-1196, 1974.
6. Goodman MF, Lee GM and Bachur NR: Adriamycin interactions with T4 DNA polymerase. Two modes of template-mediated inhibition. J Biol Chem 252: 2670-2674, 1977.
7. Tewey KM, Rowe TC, Yang L, Halligan BD and Liu LF: Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468, 1984. (Pubitemid 14012819)
8. Capranico G, Kohn KW and Pommier Y: Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 18: 6611-6619, 1990. (Pubitemid 20386590)
9. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM and Wang JC: Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85: 7177-7181, 1988. (Pubitemid 18241848)
10. Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST and Mirabelli CK: Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 86: 9431-9435, 1989.
11. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D and Hickson ID: Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res 20: 5587-5592, 1992.
12. Davies SL, Jenkins JR and Hickson ID: Human cells express two differentially spliced forms of topoisomerase IIβ mRNA. Nucleic Acids Res 21: 3719-3723, 1993. (Pubitemid 23254491)
13. Järvinen TAH, Tanner M, Rantanen V, Bärlund M, Borg Å, Grénman S and Isola J: Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156: 839-847, 2000. (Pubitemid 30626942)
14. Schiff PB and Horwitz SB: Taxol stablizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
15. Kumar N: Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256: 10435-10441, 1981. (Pubitemid 12219438)
16. Rowinsky EK, Donehower RC, Jones RJ and Tucker RW: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res 48: 4093-4100, 1988. (Pubitemid 18174726)
17. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM and Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165-1172, 1989.
18. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992.
19. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726, 2002. (Pubitemid 34111379)
20. Borgna JL and Rochefort H: Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 256: 859-868, 1981.
21. Walter P, Green S, Greene G, Krust A, Bornert JM, Jeltsch JM, Staub A, Jensen E, Scrace G, Waterfield M and Chambon P: Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 82: 7889-7893, 1985. (Pubitemid 16179869)
22. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P and Chambon P: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320: 134-139, 1986. (Pubitemid 16105150)
23. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y and Shine J: Sequence and expression of human estrogen receptor complementary DNA. Science 231: 1150-1154, 1986. (Pubitemid 16016313)
24. Mosselman S, Polman J and Dijkema R: ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53, 1996.
25. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su J-L, Kliewer SA, Lehmann JM and Willson TM: Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 247: 75-78, 1998. (Pubitemid 28412528)
26. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y and Muramatsu M: Molecular cloning and characterization of human estrogen receptorβcx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26: 3505-3512, 1998. (Pubitemid 28347221)
27. Shoda T, Hirata S, Kato J and Hoshi K: Cloning of the novel isoform of the estrogen receptor beta cDNA (ERβ isoform M cDNA) from the human testicular cDNA library. J Steroid Biochem Mol Biol 82: 201-208, 2002. (Pubitemid 35435368)
28. Cowley SM, Hoare S, Mosselman S and Parker MG: Estrogen receptors α and β form heterodimers on DNA. J Biol Chem 272: 19858-19862, 1997. (Pubitemid 27340081)
29. Pace P, Taylor J, Suntharalingam S, Coombes RC and Ali S: Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α. J Biol Chem 272: 25832-25838, 1997. (Pubitemid 27438906)
30. Pettersson K, Grandien K, Kuiper GG and Gustafsson J-Å: Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor α. Mol Endocrinol 11: 1486-1496, 1997. (Pubitemid 27366759)
31. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y and Muramatsu M: The complete primary structure of human estrogen receptor β (hERβ) and its heterodimerization with ER α in vivo and in vitro. Biochim Biophys Res Commun 243: 122-126, 1998. (Pubitemid 28414201)
32. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhlidal C and Safe S: Mechanisms of transcriptional activation of bcl-2 gene expression by 17β-estradiol in breast cancer cells. J Biol Chem 274: 32099-32107, 1999. (Pubitemid 129503804)
33. Perillo B, Sasso A, Abbondanza C and Palumbo G: 17β-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 20: 2890-2901, 2000. (Pubitemid 30183508)
34. L, without alteration of p53 protein levels. Clin Cancer Res 5: 2971-2977, 1999.
35. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J-Å and Nilsson S: Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 54: 105-112, 1998. (Pubitemid 28337592)
36. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA and Ford L: Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91: 1654-1662, 1999. (Pubitemid 29479933)
37. Bergman L, Beelen MLR, Gallee MPW, Hollema H, Benraadt J and van Leeuwen FE: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356: 881-887, 2000. (Pubitemid 30706898)
38. Yoneda K, Tanji Y, Ikeda N, Miyoshi Y, Taguchi T, Tamaki Y and Noguchi S: Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in post-menopausal breast cancer patients in Japan. Cancer Lett 186: 223-230, 2002. (Pubitemid 35251830)
39. Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999.
40. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK and Dowsett M: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063, 1999. (Pubitemid 29470633)
41. Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK and Dowsett M: Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 6: 616-621, 2000. (Pubitemid 30111487)
42. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG and Farrar WB: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19: 931-942, 2001. (Pubitemid 32176267)
43. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M and von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18: 3758-3767, 2000. (Pubitemid 30846221)
44. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jäenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA and Dugan M: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606, 2001. (Pubitemid 32451796)
45. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P and Bhatnagar A: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101-2109, 2003. (Pubitemid 46606358)
46. Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, Chaudri-Ross HA and Lang R: Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist 9: 489-496, 2004. (Pubitemid 39332312)
47. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang X-Y, Algate PA, Franklin RA, Oberhaus SM, Steelman LS and McCubrey JA: Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 13: 1109-1166, 1999. (Pubitemid 29396575)
48. Lee JT Jr and McCubrey JA: The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention. Leukemia 16: 486-507, 2002.
49. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE and McCubrey JA: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218, 2004.
50. McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA and Pohnert SC: Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detect Prev 25: 375-393, 2005.
51. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
52. Matsuguchi T, Salgia R, Hallek M, Eder M, Druker B, Ernst TJ and Griffin JD: Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3 and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem 269: 5016-5021, 1994. (Pubitemid 24239485)
53. Inhorn RC, Carlesso N, Durstin M, Frank DA and Griffin JD: Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750. Proc Natl Acad Sci USA 92: 8665-8669, 1995.
54. Okuda K, Foster R and Griffin JD: Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Ann NY Acad Sci 872: 305-313, 1999. (Pubitemid 29267868)
55. Tauchi T, Boswell HS, Leibowitz D, Broxmeyer HE, Tauchi T, Boswell HS, Leibowitz D and Broxmeyer HE: Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to ras activation pathway. J Exp Med 179: 167-175, 1994. (Pubitemid 24012981)
56. Lanfrancone L, Pelicci G, Brizzi MF, Aronica MG, Casciari C, Giuli S, Pegoraro L, Pawson T, Pelicci PG and Arouica MG: Overexpression of Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/Sos and Grb2/p140 complexes to the beta receptor subunit. Oncogene 10: 907-917, 1995.
57. Karin M, Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ and Johnson GL: Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266: 1719-1723, 1994.
58. Lange-Carter CA and Johnson GL: Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science 265: 1458-1461, 1994. (Pubitemid 24306801)
59. Marais R, Light Y, Paterson HF and Marshall CJ: Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J 14: 3136-3145, 1995.
60. Xu S, Robbins D, Frost J, Dang A, Lange-Carter C and Cobb MH: MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase. Proc Natl Acad Sci USA 92: 6808-6812, 1995.
61. Marais R, Light Y, Paterson HF, Mason CS and Marshall CJ: Differential regulation of Raf-1, A-Raf and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272: 4378-4383, 1997. (Pubitemid 27078513)
62. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ and Marais R: Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18: 2137-2148, 1999. (Pubitemid 29179171)
63. Deng T and Karin M: c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. Nature 371: 171-175, 1994. (Pubitemid 24284018)
64. Davis RJ, Derijard B, Raingeaud J, Barrett T, Wu IH, Han J and Ulevitch RJ: Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267: 682-685, 1995.
65. Xing J, Ginty DD and Greenberg ME: Coupling of the Ras-MAPK pathway to gene activation by Rsk2, a growth factor regulated CREB kinase. Science 273: 959-963, 1996. (Pubitemid 26275173)
66. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998. (Pubitemid 28524494)
67. Coutant A, Rescan C, Gilot D, Loyer P, Guguen-Guillouzo C and Baffet G: PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival. Hepatology 36: 1079-1088, 2002. (Pubitemid 35253423)
68. Iijima Y, Laser M, Shiraishi H, Willey CD, Sundaravadivel B, Xu L, McDermott PJ and Kuppuswamy D: c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 277: 23065-23075, 2002. (Pubitemid 34967293)
69. Allan LA, Morrice N, Brady S, Magee G, Pathak S and Clarke PR: Inhibition of caspase-9 by phosphorylation at Thr125 by ERK MAP kinase. Nat Cell Biol 5: 647-654, 2003.
70. Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA, Mirza A, McMahon M, White MK and McCubrey JA: Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia 17: 1058-1067, 2003. (Pubitemid 36733477)
71. Wang CY, Bassuk AG, Boise LH, Thompson CB, Bravo R and Leiden JM: Activation of the granulocyte-macrophage colony-stimulating factor promoter in T cells requires cooperative binding of Elf-1 and AP-1 transcription factors. Mol Cell Biol 14: 1153-1159, 1994. (Pubitemid 24036566)
72. Davis RJ: Transcriptional regulation by MAP kinases. Mol Reprod Dev 4: 459-467, 1995.
73. Thomas RS, Tymms MJ, McKinlay LH, Shannon MF, Seth A and Kola I: ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Oncogene 23: 2845-2855, 1997.
74. Robinson MJ, Stippec SA, Goldsmith E, White MA and Cobb MH: A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 21: 1141-1150, 1998. (Pubitemid 28494712)
75. McCubrey JA, May WS, Duronio V and Mufson A: Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 14: 9-21, 2000.
76. Aplin AE, Stewart SA, Assoian RK and Juliano RL: Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J Cell Biol 153: 273-282, 2001.
77. Tresini M, Lorenzini A, Frisoni L, Allen RG and Cristofalo VJ: Lack of Elk-1 phosphorylation and dysregulation of the extracellular regulated kinase signaling pathway in senescent human fibroblast. Exp Cell Res 269: 287-300, 2001. (Pubitemid 32907170)
78. Eblen ST, Catling AD, Assanah MC and Weber MJ: Biochemical and biological functions of the N-terminal, non-catalytic domain of extracellular signal-regulated kinase 2. Mol Cell Biol 21: 249-259, 2001.
79. Adachi T, Kar S, Wang M and Carr BI: Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J Cell Physiol 192: 151-159, 2002. (Pubitemid 34747783)
80. Ponti C, Gibellini D, Boin F, Melloni E, Manzoli FA, Cocco L, Zauli G and Vitale M: Role of CREB transcription factor in c-fos activation in natural killer cells. Eur J Immunol 32: 3358-3365, 2002. (Pubitemid 36024373)
81. Fry TJ and Mackall CL: Interleukin-7: from bench to clinic. Blood 99: 3892-3904, 2002.
82. Deng X, Kornblau SM, Ruvolo PP and May WS Jr: Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance. J Natl Cancer Inst Monogr 28: 30-37, 2001.
83. Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman LS, McCubrey JA and Andreeff M: Regulation and targeting of anti-apoptotic XIAP in acute myeloid leukemia. Leukemia 17: 2081-2089, 2003. (Pubitemid 37428371)
84. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P and Grant S: Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 102: 1824-1832, 2003.
85. Troppmair J and Rapp UR: Raf and the road to cell survival: a tale of bad spells, ring bearers and detours. Biochem Pharmacol 66: 1341-1345, 2003. (Pubitemid 38373320)
86. Ley R, Balmanno K, Hadfield K, Weston C and Cook SJ: Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278: 18811-18816, 2003. (Pubitemid 36799262)
87. Weston CR, Balmanno K, Chalmers C, Hadfield K, Molton SA, Ley R, Wagner EF and Cook SJ: Activation of ERK1/2 by deltaRaf-1:ER* represses Bim expression independently of the JNK or PI3K pathways. Oncogene 22: 1281-1293, 2003. (Pubitemid 36388747)
88. Domina AM, Vrana J, Gregory MA, Hann SR and Craig RW: MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23: 5301-5315, 2004. (Pubitemid 39005806)
89. Harada H, Quearry B, Ruiz-Vela A and Korsmeyer SJ: Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and pro-apoptotic activity. Proc Natl Acad Sci USA 101: 15313-15317, 2004. (Pubitemid 39441538)
90. Marani M, Hancock D, Lopes R, Tenev T, Downward J and Lemoine NR: Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene 23: 2431-2441, 2004. (Pubitemid 38523314)
91. Gëlinas C and White E: BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 19: 1263-1268, 2006.
92. O'Neill E, Rushworth L, Baccarini M and Kolch W: Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene Raf. Science 306: 2267-2270, 2004. (Pubitemid 40024466)
93. O'Neill EE, Matallanas D and Kolch W: Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res 65: 5485-5487, 2005. (Pubitemid 40911144)
94. Yang E, Zha J, Jockel J, Boise LH, Thompson CB and Korsmeyer SJ: Bad, a hetro-dimeric partner for Bcl-xL and Bcl-2 displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
95. Pugazhenthi S, Miller E, Sable C, Young P, Heidenreich KA, Boxer LM and Reusch JE: Insulin-like growth factor-I induces Bcl-2 promoter through the transcription factor c-AMP-response element-binding protein. J Biol Chem 274: 27529-27535, 1999. (Pubitemid 129527797)
96. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ and Yang-Yen HF: The anti-apoptotic gene Mcl-1 is upregulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 19: 6195-6206, 1999. (Pubitemid 29399324)
97. Bonni A, Brunet A, West AE, Datta SR, Takasu MA and Greenberg ME: Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and independent mechanisms. Science 286: 1358-1362, 1999. (Pubitemid 129516237)
98. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE and Reusch JE: Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275: 10761-10766, 2000. (Pubitemid 30212704)
99. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg MA: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241, 1997. (Pubitemid 27456390)
100. Harada H, Becknell B, Wilm M, Mann M, Huang LJS, Taylor SS, Scott JD and Korsmeyer SJ: Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell 3: 413-422, 1999. (Pubitemid 29292598)
101. Sunayama J, Tsuruta F, Masuyama N and Gotoh Y: JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 170: 295-304, 2005. (Pubitemid 41043811)
102. Wang K, Gross A, Waksman G and Korsmeyer SJ: Mutagenesis of the BH3 domain of BAX identifies residues critical for dimerization and killing. Mol Cell Biol 18: 6083-6089, 1998. (Pubitemid 28450559)
103. Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL and Kitamura T: STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 18: 4754-4765, 1999. (Pubitemid 29415529)
104. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ, LaMarche A, Maroney AC and Johnson EM Jr: JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 8: 899-914, 2003. (Pubitemid 36782382)
105. Ernst P, Fisher JK, Avery W, Wade S, Foy D and Korsmeyer SJ: Definative hematopoiesis requires the mixed-lineage gene. Dev Cell 6: 437-443, 2004. (Pubitemid 38364574)
106. She QB, Solit DB, Ye Q, O'Reillly KE, Lobo J and Rosen N: The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 297-297, 2005. (Pubitemid 41443414)
107. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403, 2005. (Pubitemid 40193310)
108. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM and Huang DC: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305, 2005. (Pubitemid 41003019)
109. Qi XJ, Wildey GM and Howe PH: Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 281: 813-823, 2006.
110. Vrana JA, Cleaveland ES, Eastman A and Craig RW: Inducer-and cell type-specific regulation of anti-apoptotic MCL-1 in myeloid leukemia and multiple myeloma cells exposed to differentiation-inducing or microtubule-disrupting agents. Apoptosis 11: 1275-1288, 2006. (Pubitemid 44043088)
111. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J, Umezawa A and Ichijo H: Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 277: 43730-43734, 2002. (Pubitemid 36157790)
112. Maurer U, Charvet C, Wagman AS, Dejardin E and Green DR: Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760, 2006. (Pubitemid 43376126)
113. Yu J and Zhang L: The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 331: 851-858, 2005. (Pubitemid 40615516)
114. Flotho S, Valcamonica S, Mach-Pascual G, Schmahl L, Corral J, Ritterbach H, Hasle M, Arico A and Biondi CM: RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 13: 32-37, 1999. (Pubitemid 29043714)
115. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL and Radich JP: FLT3, RAS and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97: 3589-3595, 2001.
116. Garnett MJ and Marais R: Guilty as charged: B-Raf is a human oncogene. Cancer Cell 6: 313-319, 2004.
117. Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Embergber W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J and Sill H: Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 166: 3401-3408, 2006.
118. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin J, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002. (Pubitemid 34716871)
119. Fransen K, Klinntenas M, Osterstrom A, Dimberg J, Monsteis HJ and Soderkvist P: Mutation analysis of the B-Raf, A-Raf and Raf-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25: 527-533, 2004.
120. Libra L, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travali S and McCubrey JA: Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 4: 968-970, 2006.
121. Wan PT, Garnett MJ, Ros SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R: Mechanism of activation of the Raf-MEK signaling pathway by oncogenic mutations of B-Raf. Cell 116: 856-867, 2004. (Pubitemid 38410730)
122. Busca R, Abbe P, Mantous F, Aberdam E, Peyssonnaux C, Eychene A, Ortonne JP and Ballot R: Ras mediates the cAMP-dependent activation of extracellular signal-regulated in melanocytes. EMBO J 19: 2900-2910, 2000. (Pubitemid 30386762)
123. Garnett MJ, Rana S, Paterson H, Barford D and Marais R: Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20: 963-969, 2005. (Pubitemid 41814884)
124. Rushworth LK, Hindley AD, O'Neil E and Kolch W: Regulation and role of Raf-1.B-Raf heterodimerization. Mol Cell Biol 26: 2262-2272, 2006.
125. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KN, Vogelstein B and Velculescu VE: Tumorigenesis: Raf/Ras oncogenes and mismatch-repair status. Nature 418: 934, 2002.
126. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R and Leung SY: Similarity of the phenotypic patterns associated with B-Raf and KRAS mutations in colorectal neoplasia. Cancer Res 62: 6451-6455, 2002. (Pubitemid 35364105)
127. Drexler HG: Expression of the FLT-3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 10: 588-599, 1996. (Pubitemid 26144436)
128. Rao P and Mufson RA: A membrane proximal domain of the human interleukin-3 receptor beta c subunit that signals DNA synthesis in NIH 3T3 cells 1995 specifically binds a complex of Src and Janus family tyrosine kinases and phosphatidylinositol 3-kinase. J Biol Chem 270: 6886-6893, 1995.
129. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17: 590-603, 2003. (Pubitemid 36395654)
130. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PN, Blalock WL, Franklin RA and McCubrey JA: Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int J Oncol 22: 469-480, 2003.
131. Songyang Z, Baltimore D, Cantley LC, Kaplan DR and Franke TF: Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci USA 94: 11345-11350, 1997. (Pubitemid 27451001)
132. Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R and Dedhar S: Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 278: 22374-22378, 2003. (Pubitemid 36830287)
133. Xu Z, Ma DZ, Wang LY, Su JM and Zha XL: Transforming growth factor-beta1 stimulated protein kinase B serine-473 and focal adhesion kinase tyrosine phosphorylation dependent on cell adhesion in human hepatocellular carcinoma SMMC-7721 cells. Biochim Biophys Res Commun 312: 388-396, 2003. (Pubitemid 37445185)
134. Persad S and Dedhar S: The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev 22: 375-384, 2003. (Pubitemid 36791893)
135. Kumar AS, Naruszewicz I, Wang P, Leung-Hagesteijn C and Hannigan GE: ILKAP regulates ILK signaling and inhibits anchorage-independent growth. Oncogene 23: 3454-3461, 2004. (Pubitemid 38669835)
136. Del Peso L, Gonzalez-Garcia M, Page C, Herrera R and Nunez G: Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689 1997. (Pubitemid 27464966)
137. Scheid MP and Duronio V: Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci USA 95: 7439-7444, 1998.
138. Nakae J, Park BC and Accili D: Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 274: 15982-15985, 1999. (Pubitemid 129526339)
139. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96: 857-868, 1999. (Pubitemid 29165088)
140. Medema RH, Kops GJ, Bos JL and Burgering BM: Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782-787, 2000.
141. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L and Coffer PJ: Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27Kip1. Mol Cell Biol 20: 9138-9148, 2000. (Pubitemid 32246103)
142. Mayo LD and Donner DB: A phopphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 10983-10985, 2001.
143. Gottlieb TM, Leal JF, Seger R, Taya Y and Oren M: Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21: 1299-1303, 2002. (Pubitemid 34185247)
144. Zhou BP and Hung MC: Novel targets of Akt, p21(Cip1.WAF1) and MDM2. Semin Oncol 29: 62-70, 2002.
145. Dan HC, Sun M, Naneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK and Cheng JQ: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279: 5405-5412, 2004. (Pubitemid 38220563)
146. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, Villunger A and Mak TW: FOXO3α-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 203: 1657-1663, 2006. (Pubitemid 44036270)
147. Obexer P, Geiger K, Ambros PF, Meister B and Ausseriechner MJ: FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ 14: 534-547, 2007. (Pubitemid 46259961)
148. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LLM and Donner DB: NF-kappaB activation by tumor necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85, 1999. (Pubitemid 29418447)
149. Romashkova JA and Makarov SS: NF-kappaB is a target of Akt in anti-apoptotic PDGF signaling. Nature 401: 86-90, 1999. (Pubitemid 29418448)
150. Mayo MW and Baldwin AS: The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochem Biophys Acta 1470: M55-M62, 2000.
151. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS and Mayo MW: Akt suppresses apoptosis by stimulating the transactivation potential of the Rel A/p65 subunit of NF-kappaB. Mol Cell Biol 20: 1626-1638, 2000.
152. Howe CJ, LaHair MM, Maxwell JA, Lee JT, Robinson PJ, Rodriguez-Mora OM, McCubrey JA and Franklin RA: Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. J Biol Chem 277: 30469-30476, 2002.
153. Howe CJ, LaHair MM, McCubrey JA and Franklin RA: Redox regulation of the CaM-kinases. J Biol Chem 279: 44573-44581, 2004.
154. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R and Hung MC: IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3α. Cell 117: 225-237, 2004. (Pubitemid 38496242)
155. Franklin RA, Rodriguez-Mora OG, LaHair MM and McCubrey JA: Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxid Redox Signal 8: 1807-1817, 2006.
156. Garcia R, Franklin RA and McCubrey JA: Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors. Cell Cycle 5: 1840-1846, 2006.
157. LaHair MM, Howe CJ, Rodriguez-Mora OG, McCubrey JA and Franklin RA: Molecular pathways leading to oxidative stress-induced phosphorylation of Akt. Antioxid Redox Signal 8: 1749-1756, 2006.
158. Garcia R, Franklin RA and McCubrey JA: EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 5: 2820-2826, 2006. (Pubitemid 44901745)
159. Rodriguez-Mora OG, LaHair MM, Evans MJ, Kovacs CJ, Allison RR, Sibata CH, White KS, McCubrey JA and Franklin RA: Inhibition of the CaM-Kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cells. Cancer Biol Ther 5: 1022-1030, 2006.
160. Shishodia S and Aggarwal BB: Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angio-genesis and metastasis of cancer. Cancer Treat Res 119: 139-173, 2004.
161. Du K and Montminy M: CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273: 32377-32379, 1998. (Pubitemid 28557606)
162. Arcinas M, Heckman CA, Mehew JW and Boxer LM: Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma. Cancer Res 61: 5202-5206, 2001. (Pubitemid 32681554)
163. Mahalingam M and Templeton DJ: Constitutive activation of S6 kinase by deletion of amino-terminal autoinhibitory and rapamycin sensitivity domains. Mol Cell Biol 16: 405-413, 1996. (Pubitemid 126506988)
164. Dufner A, Anjelkovic M, Burgering BMT, Hemmings B and Thomas G: Protein kinase B localization and activation and eukaryotic translational initiation factor 4E-binding protein phosphorylation. Mol Cell Biol 19: 4525-4534, 1999.
165. Romanelli A, Martin KA, Toker A and Bleinis J: p70 S6 Kinase is regulated by protein kinase Cζ and participates in a phosphoinositide 3-kinase-regulated signaling complex. Mol Cell Biol 19: 2921-2928, 1999. (Pubitemid 29144537)
166. Harada H, Andersen JS, Mann M, Terada N and Korsmeyer SJ: P70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule Bad. Proc Natl Acad Sci USA 98: 9666-9670, 2001. (Pubitemid 32769360)
167. Edinger AL and Thompson CB: An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene 23: 5654-5663, 2004.
168. Panwalkar A, Verstovsek S and Giles FJ: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100: 657-666, 2004. (Pubitemid 38176841)
169. Jonassen AK, Mjos OD and Sack MN: p70S6 kinase is a functional target of insulin activated Akt cell-survival. Biochem Biophys Res Commun 315: 160-165, 2004.
170. Ma L, Chen Z, Erdjument-Bromage H, Tempst P and Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193, 2005. (Pubitemid 40546387)
171. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943-1947, 1997.
172. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH and Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362, 1997. (Pubitemid 27147102)
173. Li DM and Sun H: TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57: 2124-2129, 1997.
174. Steelman LS, Bertrand FE and McCubrey JA: The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 8: 537-550, 2004. (Pubitemid 40028365)
175. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 441: 424-430, 2006.
176. Mahimainathan L and Choudhury GG: Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 279: 15258-15268, 2004. (Pubitemid 38618922)
177. Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S and Hall A: Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 303: 1179-1181, 2004. (Pubitemid 38233580)
178. Damen JE, Liu L, Rosten P, Humphries RK, Jefferson AB, Majerus PW and Krystal G: The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triposphate 5-phosphatase. Proc Natl Acad Sci USA 93: 1689-1693, 1996. (Pubitemid 26075186)
179. Kavanaugh WM, Pot DA, Chin SM, Deuter-Reinhard M, Jefferson AB, Norris FA, Masiarz FR, Cousens LS, Majerus PW and Williams LT: Multiple forms of an inositol polyphosphate 5-phosphaatase from signaling complexes with Shc and Grb2. Curr Biol 6: 438-445, 1996. (Pubitemid 126656291)
180. Lioubin MN, Algate PA, Tsai S, Carlberg K, Aebersold A and Rohrschneider LR: P150Ship, a signal transduction molecule with inositol polyphosphate-5- phosphatase activity. Genes Devel 10: 1084-1095, 1996. (Pubitemid 26152850)
181. Muraille E, Pesesse X, Kuntz C and Erneux C: Distribution of the src-homology-2-domain-containing inositol 5-phosphatase SHIP-2 in both non-haemopoietic and haemopoietic cells and possible involvement in SHIP-2 in negative signaling of B-cells. Biochem J 342: 697-705, 1999. (Pubitemid 29452656)
182. Taylor V, Wong M, Brandts C, Reilly L, Dean NM, Cowsert LM, Moodie S and Stokoe D: 5'Phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 20: 6860-6871, 2000. (Pubitemid 30700803)
183. Rommel C, Clarke BA, Zimmermann S, Nuñez L, Rossman R, Reid K, Moelling K, Yancopoulos GD and Glass DJ: Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286: 1738-1741, 1999. (Pubitemid 129515881)
184. Zimmermann S and Moelling K: Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286: 1741-1744, 1999. (Pubitemid 129515882)
185. Guan K, Figueroa C, Brtva TR, Zhu T, Taylor J, Barber TD and Vojtek AB: Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 275: 27354-27359, 2000. (Pubitemid 30688096)
186. Zhang BH, Tang E, Zhu T, Greenberg M, Vojtek A and Guan KL: Serum and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf. J Biol Chem 276: 31620-31626, 2001. (Pubitemid 37384806)
187. Majewski M, Nieborowska-Skorska M, Salomoni P, Slupianek A, Reiss K, Trotta R, Calabretta B and Skorski T: Activation of mitochondrial Raf-1 is involved in the anti-apoptotic effects of Akt. Cancer Res 59: 2815-2819, 1999. (Pubitemid 29283115)
188. McCubrey JA, Steelman LS, Blalock WL, Lee JT, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA and Pohnert SC: Synergistic effects of PI3K/Akt on abrogation of cytokine-dependency induced by oncogenic Raf. Adv Enzyme Regul 41: 289-323, 2001. (Pubitemid 32520330)
189. Gelfanov VM, Burgess GS, Litz-Jackson S, King AJ, Marshall MS, Nakshatri H and Boswell HS: Transformation of interleukin-3-dependent cells without participation of Stat5/Bcl-xL:cooperation of akt with raf/erk leads to p65 nuclear factor κB-mediated anti-apoptosis involving c-IAP2. Blood 15: 2508-2517, 2001.
190. Von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR and Troppmair J: Apoptosis suppression by Raf-1 and MEK1 requires MEK and phosphatidylinositol 3-kinase dependent signals. Mol Cell Biol 21: 2324-2336, 2001. (Pubitemid 32222086)
191. Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, Franklin RA, Pohnert SC, Mirza AM, McMahon M and McCubrey JA: Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene 22: 2478-2492, 2003. (Pubitemid 36560731)
192. Shelton JG, Blalock WL, White ER, Steelman LS and McCubrey JA: Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle 3: 503-512, 2004.
193. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB and Andreeff M: Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18: 267-275, 2004. (Pubitemid 38240042)
194. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F and Rauen KA: Germline mutations in genes within the MAPK pathway cause cardiofacio-cutaneous syndrome. Science 311: 1287-1290, 2006. (Pubitemid 43334718)
195. Gire V, Marshall C and Wynford-Thomas D: PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS. Oncogene 19: 2269-2276, 2000. (Pubitemid 30307202)
196. Sun H, King AJ, Diaz HB and Marshall MS: Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. Curr Biol 10: 281-284, 2000. (Pubitemid 30152952)
197. Hu L, Shi Y, Hsu JH, Gera J, van Ness B and Lichtenstein A: Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101: 3126-3135, 2003. (Pubitemid 36858006)
198. Kubota Y, Ohnishi H, Kitanaka A, Ishida T and Tanaka T: Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia 18: 1438-1440, 2004. (Pubitemid 39136758)
199. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sánchez A, Martín-Saavedra FM, Ballester S, García-Marco J, Jordá J and Durántez A: A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18: 1391-1400, 2004. (Pubitemid 39136749)
200. Ninomiya Y, Kato K, Takahashi A, Ueoka Y, Kamikihara T, Arima T, Matsuda T, Kato H, Nishida J and Wake N: K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res 64: 2759-2765, 2004. (Pubitemid 38500613)
201. Jucker M, Sudel K, Horn S, Sickel M, Wegner W, Fiedler W and Feldman RA: Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 16: 894-901, 2002. (Pubitemid 34537563)
202. Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929, 2005. (Pubitemid 41766781)
203. Engleman JA, Luo J and Canley LC: The evolution phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619, 2006. (Pubitemid 44100518)
204. Vogt PK, Bader AG and Kang S: Phosphoinositide 3-kinase: from viral oncoprotein to drug target. Virology 344: 131-138, 2006.
205. Kang S, Bader AG, Zhao L and Vogt PK: Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 4: 578-581, 2005. (Pubitemid 41359785)
206. Müller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, Luong QT and Koeffler HP: Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 31: 27-32, 2007. (Pubitemid 44709746)
207. Nakahara Y, Nagai H, Kinoshita T, Uchida T, Hatano S, Murate T and Saito H: Mutational analysis of the PTEN/ MMAC1 gene in non-Hodgkin's lymphoma. Leukemia 12: 1277-1280, 1998. (Pubitemid 28395992)
208. Sakai A, Thieblemont C, Wellmann A, Jaffe ES and Raffeld M: PTEN gene alterations in lymphoid neoplasms. Blood 92: 3410-3415, 1998. (Pubitemid 28492352)
209. Dahia PL, Aquiar RC, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ, Ritz J, Freedman A, Stiles C and Eng C: PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanism in haematological malignancies. Human Mol Gen 8: 185-193, 1999. (Pubitemid 29054260)
210. Butler MP, Wang SI, Chaganti RS, Parsons R and Dalla- Favera R: Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes Chromosomes Cancer 24: 322-327, 1999. (Pubitemid 29115870)
211. Aggerholm A, Gronbaek K, Guldberg P and Hokland P: Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Eur J Haematol 65: 109-113, 2000. (Pubitemid 30615084)
212. Leslie NR, Gray A, Pass I, Orchiston EA and Downes CP: Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signaling pathways downstream of phosphoinositide 3-kinase. Biochem J 346: 827-833, 2000. (Pubitemid 30171047)
213. Herranz M, Urioste M, Santos J, Martinez-Delgado JB, Rivas C, Benitez J and Fernández-Piqueras J: Allelic losses and genetic instabilities of PTEN and p73 in non-Hodgkin lymphomas. Leukemia 14: 1325-1327, 2000. (Pubitemid 30445047)
214. Staal SP: Molecular cloning of the Akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84: 5034-5037, 1987.
215. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR: AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 89: 9267-9271, 1992.
216. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK and Testa JR: Amplification of AKT2 in human pancreatic cells and inhibiton of AKT2 expression and tumorigenicity by anti-sense RNA. Proc Natl Acad Sci USA 93: 3636-3641, 1996. (Pubitemid 26127592)
217. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL and Neubauer BL: Increased Akt activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip-1 expression. J Biol Chem 275: 24500-24505, 2000. (Pubitemid 30626543)
218. Luo JM, Yoshida H, Komura S, Ohishi N, Pan L, Shigeno K, Hanamura I, Miura K, Iida S, Ueda R, Naoe T, Akao Y, Ohno R and Ohnishi K: Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia 17: 1-8, 2003. (Pubitemid 36175881)
219. Luo JM, Liu ZL, Hao HL, Wang FX, Dong ZR and Ohno R: Mutation analysis of SHIP gene in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 12: 420-426, 2004.
220. Lin J, Adam RM, Santiestevan E and Freeman MR: The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59: 2891-2897, 1999. (Pubitemid 29283128)
221. Hietakangas V and Cohen SM: Re-evaluating Akt regulation: role of TOR complex 2 in tissue growth. Genes Dev 21: 632-637, 2007. (Pubitemid 46440284)
222. Fry MJ: Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? Breast Cancer Res 3: 304-312, 2001.
223. Lin X, Bohle AS, Dohrmann P, Leuschner I, Schulz A, Kremer B and Fändrich F: Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 386: 293-301, 2001. (Pubitemid 32702759)
224. Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A, Herlyn M and Ronai Z: Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma cells. Mol Carcinog 24: 64-69, 1999. (Pubitemid 29070245)
225. Martinez-Lorenzo MJ, Anel A, Monleon I, Sierra JJ, Piñeiro A, Naval J and Alava MA: Tyrosine phosphorylation of the p85 subunit of phosphatidylinositol 3-kinase correlates with high proliferation rates in sublines derived from the Jurkat leukemia. Int J Biochem Cell Biol 32: 435-445, 2000. (Pubitemid 30101624)
226. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935, 2004. (Pubitemid 38868139)
227. Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL and Lykkesfeldt AE: Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 12: 599-614, 2005. (Pubitemid 41482995)
228. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A and Bartlett JM: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207: 139-146, 2005. (Pubitemid 41404144)
229. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH and Andreeff M: Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108: 2358-2365, 2006. (Pubitemid 44497520)
230. Nyakern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T, Piccaluga PP, Martinelli G, Cocco L and Martelli AM: Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 20: 230-238, 2006. (Pubitemid 43148660)
231. Mantovani I, Cappellini A, Tazzari PL, Papa V, Cocco L and Martelli AM: Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. J Cell Physiol 207: 836-844, 2006. (Pubitemid 43668249)
232. Nyakern M, Cappellini A, Mantovani J and Martelli AM: Synergistic induction of apoptosis in yhuman leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther 5: 1559-1570, 2006. (Pubitemid 44070493)
233. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C and Cocco L: Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myelid leukemia. Leukemia 20: 911-928, 2006. (Pubitemid 43797279)
234. Navolanic PM, Steelman LS and McCubrey JA: EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 22: 237-252, 2003.
235. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI and Boyd J: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 57: 3657-3659, 1997. (Pubitemid 27381202)
236. Singh B, Ittmann MM and Krolewski JJ: Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes Chromosome Cancer 21: 166-171, 1998. (Pubitemid 28081244)
237. Feilotter HE, Coulon V, McVeigh JL, Boag AH, Dorion-Bonnet F, Duboue B, Latham WC, Eng C, Mulligan LM and Longy M: Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer 79: 718-723, 1999. (Pubitemid 29082095)
238. DeGraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M and Hidalgo M: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncology 15: 1510-1516, 2004. (Pubitemid 39409742)
239. Hollestelle A, Elstrodt F, Nagel JHA and Kallemeijn WW: Phosphatidylinositol-3-OH kinase or Ras pathway mutations in human breast cancer cell lines. Mol Cancer Res 5: 195-201, 2007. (Pubitemid 46424000)
240. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, Cantos B, Provencio M, Espana P and Bonilla R: Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41: 117-124, 2004. (Pubitemid 39096737)
241. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S and Mori M: Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 68: 398-404, 2005. (Pubitemid 41160970)
242. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X and Pandolfi PP: Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128: 141-156, 2007. (Pubitemid 46048885)
243. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP and Yin Y: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170, 2007. (Pubitemid 46048887)
244. Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H and Maehara Y: Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 13: 137-144, 2006.
245. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA and Stratton MR: Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158, 2007. (Pubitemid 46398669)
246. Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M and McCubrey JA: The epidermal growth factor receptor as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opin Ther Targets 9: 1009-1030, 2005.
247. Deng X, Xiao L, Lang W, Gao F, Ruvolo P and May WS Jr: Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem 276: 23681-23688, 2001. (Pubitemid 37410761)
248. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA and Cocco L: Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 14: 2009-2023, 2007. (Pubitemid 47578159)
249. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD and Mehta K: Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 21: 8843-8851, 2002. (Pubitemid 36132404)
250. Liang Y, Yan C and Schor NF: Apoptosis in the absence of caspase 3. Oncogene 20: 6570-6578, 2001.
251. Twiddy D, Gohen GM, MacFarlane M and Cain K: Casape-7 is directly activated by the ∼700-kDa apoptosome complex and is released as a stable XIAP-caspase-7 ∼200-kDa complex. J Biol Chem 281: 3876-3888, 2006. (Pubitemid 43847811)
252. Gardai SJ, Whitlock BB, Xiao YQ, Bratton DB and Henson PM: Oxidants inhibit ERK/MAPK and prevent its ability to delay neutrophil apoptosis downstream of mitochondrial changes and at the level of XIAP. J Biol Chem 279: 44695-44703, 2004.
253. Lee JT Jr and McCubrey JA: Targeting the Raf kinase cascade in cancer therapy-novel molecular targets and therapeutic strategies. Expert Opin Ther Targets 6: 659-678, 2002.
254. Hochhaus A, McCubrey JA and Killmann NMB: Spotlight imatinib: a model for signal transduction inhibitors. Leukemia 16: 1205-1206, 2002.
255. Barnes G, Bulusu VR, Hardwick RH, Carroll N, Hatcher H, Earl HM, Save VE, Balan K and Jamieson NV: A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec trade mark). Int J Surg 3: 206-212, 2005.
256. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Bannigan BW, Harris PL, Haserlat SM, Supko JB, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
257. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004. (Pubitemid 39100331)
258. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H: EGF receptor mutations are common in lung cancers from 'never smokers' are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
259. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: 57-61, 2005. (Pubitemid 40412734)
260. Sequist LV, Haber DA and Lynch TJ: Epidermal growth factor receptor mutations in non-small cell lung cancer; predicting clinical response to kinase inhibitors. Clin Cancer Res 11: 5668-5670, 2005. (Pubitemid 41170288)
261. Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A and Milella M: Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumors and hematological malignancies. Drug Resist Updat 10: 81-100, 2007. (Pubitemid 47031052)
262. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H and Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058, 2005. (Pubitemid 41161231)
263. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC and Andreeff M: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388, 2006. (Pubitemid 44693472)
264. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W and Andreeff M: MDM2 inhibitor Nutlin 3a induces p53-mediated apoptosis by transcription- dependent and transcriptionindependent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108: 993-1000, 2006. (Pubitemid 44154636)
265. Heimbrook DC, Huber HE, Stirdivant SM, Claremon D, Liverton N, Patrick DR, Selnick H, Ahern J, Conroy R, Drakas R, Falconi N and Hancock P: Identification of potent, selective kinase inhibitors of Raf. Proc Am Assoc Cancer Res Annual Meeting 39: 558, 1998.
266. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H and Hedge P: Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 6: 559-568, 1999. (Pubitemid 29380770)
267. Lyons JF, Wilhelm S, Hibner B and Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8: 219-225, 2001. (Pubitemid 32947644)
268. Blagosklonny MV: Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16: 455-462, 2002.
269. Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA, McMahon M and McCubrey JA: Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17: 1765-1782, 2003. (Pubitemid 37185253)
270. Lee JT, Steelman LS and McCubrey JA: PI3K Activation leads to MRP1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64: 8397-8404, 2004.
271. Workman P: Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10: 47-51, 2004.
272. Shimamura T, Lowell AM, Engelman JA and Shapiro GI: Epidermal growth
273. Sain N, Krishnan B, Ormerod MG, De Rienzo A, Liu WM, Kaye SB, Workman P and Jackman AL: Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 5: 1197-1208, 2006. (Pubitemid 43881312)
274. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD and Downward J: Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527-532, 1994. (Pubitemid 24264918)
275. Delaney AM, Printon JA, Chen H, Faumann EB and Dudley DT: Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol Cell Biol 22: 7593-7602, 2002.
276. Davies SP, Reddy H, Caivano M and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000. (Pubitemid 30781561)
277. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H and Hasemann CA: Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel non-com-petitive kinase inhibition. Nat Struct Mol Biol 11: 1192-1197, 2004.
278. Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial I and Anderson KC: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood 110: 1656-1663, 2006. (Pubitemid 47443984)
279. Wang D, Boerner SA, Winkler JD and LoRusso PM: Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773: 1248-1255, 2007. (Pubitemid 47161034)
280. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, Evans RJ, Parry J, Smith D, Brandhuber BJ, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee PA, Winkler JD, Koch K and Wallace E: Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13: 1576-1583, 2007. (Pubitemid 46450450)
281. Mazzucchelli C, Vantaggiato C, Ciamei A, Fasano S, Pakhotin P, Krezel W, Welzl H, Wolfer DP, Pages G, Valverde O, Marowsky A, Porrazzo A, Orban PC, Maldonado R, Ehrengruber MU, Cestari V, Lipp HP, Chapman PF, Pouysségur J and Brambilla R: Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 34: 807-820, 2002. (Pubitemid 34628742)
282. Rolfe M, McLeod LE, Pratt PF and Proud CG: Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem J 388: 973-984, 2005. (Pubitemid 40941586)
283. Sosman JA, Puzanov I and Atkins MB: Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 13: 764s-769s, 2007. (Pubitemid 46220112)
284. Costa LJ, Gemmill RM and Drabkin HA: Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology 69: 596-602, 2007.
285. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA and Giaccone G: Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 118: 209-214, 2006. (Pubitemid 41681601)
286. Wang LH, Chan JLK and Li W: Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Int J Cancer 121: 2911-2918, 2007.
287. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC and Slamon DJ: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639, 2006. (Pubitemid 43259947)
288. Yu C, Mao X and Li WX: Inhibition of the PI3K pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun 331: 391-397, 2005. (Pubitemid 40602650)
289. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB and Meric-Bernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cyto-toxicity in breast cancer cells. Clin Cancer Res 10: 7031-7042, 2004. (Pubitemid 39383055)
290. Faried LS, Kanuma T, Nakazato T, Tamura T, Kuwano H and Minegishi T: Inhibition of the mammalian target of Rapamycin (mTOR) by Rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Can 42: 934-947, 2006.
291. Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC and Meric-Bernstam F: Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 65: 1961-1972, 2005.
292. Hahn M, Li W, Yu C, Rahmani M, Dent P and Grant S: Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 4: 457-470, 2005.
293. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, Dent P and Grant S: Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 105: 1706-1716, 2005. (Pubitemid 40223694)
294. Yu K, Lucas J, Zhu T, Zask A, Gaydos C, Toral-Barza L, Gu J, Li F, Chaudhary I, Cai P, Lotvin J, Petersen R, Ruppen M, Fawzi M, Ayral-Kaloustian S, Skotnicki J, Mansour T, Frost P and Gibbons J: PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther 4: 538-545, 2005. (Pubitemid 41351227)
295. Abdul-Ghani R, Serra V, Gyorffy B, Jürchott K, Solfmm A, Dietel M and Schäfer R: The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP-1. Oncogene 25: 1743-1752, 2006.
296. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG and Anderson KC: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107: 4053-4062, 2006.
297. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA and Martelli AM: The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 21: 886-896, 2007. (Pubitemid 46672063)
298. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, De Jong R, Han EK, Li T, Stoll VS, Powlas JA, Oleksijew A, Mitten MJ, Shi Y, Guan R, McGonigal TP, Klinghofer V, Johnson EF, Leverson JD, Bouska JJ, Mamo M, Smith RA, Gramling-Evans EE, Zinker BA, Mika AK, Nguyen PT, Oltersdorf T, Rosenberg SH, Li Q and Giranda VL: Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4: 977-986, 2005. (Pubitemid 40909080)
299. Zhong X, Li X, Wang G, Zhu Y, Hu G, Zhao J, Neace C, Ding H, Reed E and Li QQ: Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int J Oncol 25: 445-451, 2004.
300. Sosman JA and Puzanov I: Molecular targets in melanoma from angiogenesis to apoptosis. Clin Cancer Res 12: 2376s-2383s, 2006.
301. Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M and Sebti SM: Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 105: 4759-4766, 2005. (Pubitemid 40807301)
302. MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y and Ting JP: Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 63: 6928-6934, 2003. (Pubitemid 37322978)
303. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez-Soler R and Horwitz SB: Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res 65: 2854-2860, 2005. (Pubitemid 40490089)
304. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K and Murata Y: Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277: 33490-33500, 2002. (Pubitemid 34984873)
305. Brognard J and Dennis PA: Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 9: 893-904, 2002. (Pubitemid 35023605)
306. Aoki K, Ogawa T, Ito Y and Nakashima S: Cisplatin activates survival signals in UM-SCC-23 squamous cell carcinoma and these signal pathways are amplified in cisplatin-resistant squamous cell carcinoma. Oncol Rep 11: 375-379, 2004.
307. Park SA, Park HJ, Lee BI, Ahn YH, Kim SU and Choi KS: Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 93: 18-26, 2001.
308. Lunghi P, Tabilio A, Lo-Coco F, Pelicci PG and Bonati A: Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia 19: 234-244, 2005. (Pubitemid 40220588)
309. Lunghi P, Costanzo A, Salvatore L, Noguera N, Mazzera L, Tabilio A, Lo-Coco F, Levrero M and Bonati A: MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 107: 4549-4553, 2006. (Pubitemid 43801384)
310. Dai Y, Landowski TH, Rosen ST, Dent P and Grant S: Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 100: 3333-3343, 2002. (Pubitemid 35217085)
311. Rieber M and Rieber MS: Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status. Int J Cancer 118: 1135-1143, 2006. (Pubitemid 43185599)
312. McCubrey JA, LaHair MM and Franklin RA: Reactive oxygen species-induced activation of the MAP kinase signaling pathway. Antioxid Redox Signal 8: 1745-1748, 2006. (Pubitemid 44726347)
313. Fornari FA, Randolph JK, Yalowich JC, Ritke MK and Gewirtz DA: Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharm 45: 649-656, 1994. (Pubitemid 24139191)
314. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
315. Singal PK, Li T, Kumar D, Danelisen I and Iliskovic N: Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 207: 77-86, 2000. (Pubitemid 30399372)
316. Friesen C, Fulda S and Debatin KM: Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells. Cell Death Differ 6: 471-480, 1999. (Pubitemid 29245961)
317. Narayanan PK, Goodwin EH and Lehnert BE: Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res 57: 3963-3971, 1997.
318. Kobayashi D, Tokino T and Watanabe N: Contribution of caspase-3 differs by p53 status in apoptosis induced by X-irradiation. Jpn J Cancer Res 92: 475-481, 2001. (Pubitemid 32427785)
319. Oleinick NL and Evans HH: The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 150: S146-S156, 1998. (Pubitemid 28519059)
320. Matroule JY, Carthy CM, Granville DJ, Jolois O, Hunt DW and Piette J: Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization. Oncogene 20: 4070-4084, 2001. (Pubitemid 32681612)
321. Tong Z, Singh G and Rainbow AJ: Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy. Cancer Res 62: 5528-5535, 2002.
322. Dent P, Yacoub A, Fisher PB, Hagan MP and Grant S: MAPK pathways in radiation responses. Oncogene 22: 5885-5896, 2003.
323. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S and Schmidt-Ullrich R: Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 159: 283-300, 2003. (Pubitemid 36314943)
324. Abdelmohsen K, von Montfort C, Stuhlmann D, Gerber PA, Decking UK, Sies H and Klotz LO: Doxorubicin induces EGF receptor-dependent down-regulation of gap junctional intercellular communication in rat liver epithelial cells. Biol Chem 386: 217-223, 2005. (Pubitemid 40485427)
325. Papaiahgari S, Kleeberger SR, Cho HY, Kalvakolanu DV and Reddy SP: NADPH oxidase and ERK signaling regulates hyperoxia-induced Nrf2-ARE transcriptional response in pulmonary epithelial cells. J Biol Chem 279: 42302-42312, 2004. (Pubitemid 39313679)
326. Matsuzawa A, Nishitoh H, Tobiume K, Takeda K and Ichijo H: Physiological roles of ASK1-mediated signal transduction in oxidative stress- and endoplasmic reticulum stress-induced apoptosis: advanced findings from ASK1 knockout mice. Antioxid Redox Signal 4: 415-425, 2002. (Pubitemid 34753381)
327. Minamino T, Yujiri T, Papst PJ, Chan ED, Johnson GL and Terada N: MEKK1 suppresses oxidative stress-induced apoptosis of embryonic stem cell-derived cardiac myocytes. Proc Natl Acad Sci USA 96: 15127-15132, 1999. (Pubitemid 30019776)
328. Modur V, Zimmerman G, Prescott S and McIntyre T: Endothelial cell inflammatory responses to tumor necrosis factor alpha. Ceramide-dependent and -independent mitogen-activated protein kinase cascades. J Biol Chem 271: 13094-13102, 1996. (Pubitemid 26175885)
329. Teramoto H, Coso OA, Miyata H, Igishi T, Miki T and Gutkind JS: Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase/stress-activated protein kinase pathway. A role for mixed lineage kinase 3/protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family. J Biol Chem 271: 27225-27228, 1996. (Pubitemid 26367270)
330. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K and Gotoh Y: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275: 90-94, 1997.
331. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T and Ichijo H: ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2: 222-228, 2001. (Pubitemid 32273301)
332. Suzaki Y, Yoshizumi M, Kagami S, Koyama AH, Taketani Y, Houchi H, Tsuchiya K, Takeda E and Tamaki T: Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: potential role in cell survival following oxidative insults. J Biol Chem 277: 9614-9621, 2002. (Pubitemid 34953051)
333. Kamakura S, Moriguchi T and Nishida E: Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J Biol Chem 274: 26563-26571, 1999. (Pubitemid 129520095)
334. Cavanaugh JE, Ham J, Hetman M, Poser S, Yan C and Xia Z: Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci 21: 434-443, 2001. (Pubitemid 32107434)
335. Touyz RM, Yao G, Viel E, Amiri F and Schiffrin EL: Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 22: 1141-1149, 2004. (Pubitemid 38721006)